Header cover image

Danish Pharmaceuticals & Biotech Established, Profitable and Undervalued

UPDATED Aug 13, 2022

Over $1bn in market cap, profitable and undervalued based on cash flows.

2 companies
CompanyLast Price7D Return1Y ReturnMarket CapAnalysts TargetValuationGrowthDiv Yield
NOVO BNovo Nordiskkr.770.001.9%19.0%kr.1.7tkr.827.04PE34.5xE13.6%1.4%
GMABGenmabkr.2,636.003.1%-10.6%kr.172.1bkr.2,680.59PE43.4xE23.1%n/a
Page 1 of 1